Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$ACHV Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.80 down -116.22% YoY • Achieve Life Sciences anticipates potential FDA approval for cytisinicline in the first half of 2027, which will be followed by a U.S. commercial launch of the treatment for nicotine dependence.
1

Price since post

Full Details

Advertisement|Remove ads.